CD8A and neoplasm: Promising immune-activating effects have been achieved upon simultaneous targeting of T cell coreceptor CD3ε and PD-L1, which has been shown to rejuvenate anti-tumor T cell response by alleviating DC-mediated PD-L1 suppression while increasing B7-1&2 costimulation (Liu et al., 2018, 2021).